Of the different breast cancer subtypes, triple negative breast cancer (TNBC) patients, who lack expression of Estrogen or Progesterone Receptors (ER or PR) or Human EGF Receptor 2 (HER2) in their tumors, have the worst outcome and we lack a targeted therapy for this group. Here, ERBB2 is linked to triple-negative breast carcinoma.